Immune tolerance induction with highly purified plasma-derived factor VIII containing von Willebrand factor in hemophilia A patients with high-responding inhibitors.
We retrospectively evaluated the efficacy of immune tolerance induction (ITI) in a homogenous cohort of eight patients with constitutive severe hemophilia A with high-responding factor VIII (FVIII) inhibitors using Facteur VIII-LFB/Factane, a highly purified FVIII concentrate containing von Willebrand factor (VWF).
Orsini
Frédérique
F
Rotschild
Chantal
C
Beurrier
Philippe
P
Faradji
Albert
A
Goudemand
Jenny
J
Polack
Benoît
B
D002648:Child; D002675:Child, Preschool; D005169:Factor VIII / Q000037:antagonists & inhibitors* / Q000276:immunology* / Q000378:metabolism; D006467:Hemophilia A / Q000097:blood / Q000276:immunology*; D006801:Humans; D007108:Immune Tolerance; D007223:Infant; D012189:Retrospective Studies; D014842:von Willebrand Diseases / Q000097:blood / Q000276:immunology; D014841:von Willebrand Factor / Q000037:antagonists & inhibitors* / Q000276:immunology* / Q000378:metabolism
D014841:von Willebrand Factor; D005169:Factor VIII